Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760711 | 0.93 | CHRM2 (0.42) | ELANECHRM2CHRM1ALDH1A1LMNA | |
| SCHEMBL6757054 | 0.90 | CHRM2 (0.52) | ELANECHRM2CHRM1ALDH1A1CYP3A4 | |
| SCHEMBL6761854 | 0.84 | CHRM2 (0.42) | CHRM2CHRM1ALDH1A1CYP3A4LMNA | |
| SCHEMBL3772904 | 0.82 | ALOX15 (0.41) | CHRM2CHRM1ALDH1A1LMNA | |
| SCHEMBL2167092 | 0.81 | CHRM2 (0.64) | ELANECHRM2CHRM1ALDH1A1LMNA | |
| SCHEMBL6539682 | 0.79 | CHRM2 (0.39) | ELANECHRM2CHRM1ALDH1A1CYP3A4 | |
| SCHEMBL6760480 | 0.77 | CHRM2 (0.51) | ELANECHRM2CHRM1CYP3A4 | |
| SCHEMBL2166559 | 0.76 | CHRM2 (0.66) | ELANECHRM2CHRM1LMNAADRB2 | |
| SCHEMBL5269800 | 0.75 | CHRM2 (0.37) | ELANECHRM2CHRM1ALDH1A1LMNA | |
| SCHEMBL8096707 | 0.74 | LMNA (0.37) | CHRM2CHRM1CYP3A4LMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855230-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | ELANE 4204/4885CHRM2 140/4885CHRM1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.